Advanced in Pure Red Cell Aplasia

Dr. Jason Gotlib

Hematology

Stanford University

875 Blake Wilbur Dr,

Palo Alto, CA

Clinical Trials:Currently Recruiting for 1 Trial

Offers Telehealth

Advanced in Pure Red Cell Aplasia

Stanford University

875 Blake Wilbur Dr,

Palo Alto, CA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Gotlib is a Hematologist in Palo Alto, California. Dr. Gotlib is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy.

His clinical research consists of co-authoring 244 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pure Red Cell Aplasia.

Specialties

Hematology

Licenses

Internal Medicine in CA

Hospital Affiliations

Stanford Health Care Tri-Valley

Community Hospital Of The Monterey Peninsula

Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Alignment Health Plan

MEDICARE MAPD
MEDICARE SNP
OTHER MEDICARE
OTHER MEDICARE PART D

Anthem BCBS

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 5 Less Insurance Carriers -

Locations

Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Call: 650-498-6000

Other Locations

Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305

Call: 650-498-4940

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

Enrollment Status: Recruiting

Publish Date: December 23, 2025

Intervention Type: Drug

Study Drug: Ruxolitinib

Study Phase: Phase 2

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Enrollment Status: Completed

Publish Date: November 18, 2025

Intervention Type: Drug

Study Phase: Phase 2

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2025

Intervention Type: Drug

Study Drug: Avapritinib

Study Phase: Phase 2

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Enrollment Status: Completed

Publish Date: April 30, 2025

Intervention Type: Drug

Study Drug: Avapritinib

Study Phase: Phase 2

Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)

Enrollment Status: Completed

Publish Date: January 06, 2025

Intervention Type: Drug

Study Drug: Tagraxofusp

Study Phase: Phase 1/Phase 2

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Enrollment Status: Completed

Publish Date: March 17, 2023

Intervention Type: Drug

Study Drug: Avapritinib

Study Phase: Phase 1

Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R

Enrollment Status: Completed

Publish Date: November 16, 2020

Intervention Type: Other, Drug

Study Phase: Phase 2

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Enrollment Status: Completed

Publish Date: April 30, 2019

Intervention Type: Drug

Study Phase: Phase 3

A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)

Enrollment Status: Completed

Publish Date: January 29, 2019

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis

Enrollment Status: Terminated

Publish Date: September 20, 2018

Intervention Type: Drug

Study Phase: Phase 2

Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Enrollment Status: Completed

Publish Date: May 31, 2018

Intervention Type: Procedure

A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia

Enrollment Status: Terminated

Publish Date: May 14, 2018

Intervention Type: Drug

Study Phase: Phase 1

View 12 Less Clinical Trials

244 Total Publications

Introduction to a How I Treat series on chronic myeloid leukemia.

Journal: Blood

Published: November 13, 2025

View All 244 Publications

Similar Doctors

Elite in Pure Red Cell Aplasia

Dr. Bertil Glader

Hematology

Elite in Pure Red Cell Aplasia

Dr. Bertil Glader

Hematology

Lucile Packard Children's Hospital Stanford

725 Welch Rd,

Palo Alto, CA

(0.1 miles away)

650-497-8953

Languages Spoken:

English

See accepted insurances

Bertil Glader is a Hematologist in Palo Alto, California. Dr. Glader is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Aase Syndrome, Pyruvate Kinase Deficiency, Pure Red Cell Aplasia, Hemolytic Anemia, and Splenectomy.

Elite in Pure Red Cell Aplasia

Dr. Kathleen Sakamoto

Hematology | Oncology

Elite in Pure Red Cell Aplasia

Dr. Kathleen Sakamoto

Hematology | Oncology

Office

725 Welch Rd Ste 160,

Palo Alto, CA

(4.2 miles away)

650-497-8953

Languages Spoken:

English

See accepted insurances

Kathleen Sakamoto is a Hematologist and an Oncologist in Palo Alto, California. Dr. Sakamoto is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Transient Erythroblastopenia of Childhood, Aplastic Anemia, and Bone Marrow Aspiration.

Advanced in Pure Red Cell Aplasia

Dr. Beth Martin

Hematology

Advanced in Pure Red Cell Aplasia

Dr. Beth Martin

Hematology

Stanford University

875 Blake Wilbur Dr,

Palo Alto, CA

(0.1 miles away)

650-498-6000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Beth Martin is a Hematologist in Palo Alto, California. Dr. Martin is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

VIEW MORE PURE RED CELL APLASIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gotlib's expertise for a condition

ConditionClose